Moreover, CPT is commonly used in clinical treatment in rectal cancer [43, 44], which further proves that PRDM15 is associated with poor clinical prognosis, and also confirms that PRDM15 could also be a potential target for the combined treatment with CPT. This evidence concerns the gene PRDM15 and rectal cancer.